All stakeholders want to maintain our leading position on access, which will perhaps require even closer collaboration with the Medicines Council and Amgros, making sure that…
In Conversation
There is a wealth of knowledge in Denmark, especially in the cardiometabolic area, and a strong culture of collaboration, to which we contribute and benefit from
Celltrion is a true pioneer in biosimilars. Our objective at the moment is to launch at least one product per year; we try to be very…
There is great potential for improvement if pharma companies can use agreed-upon standards for collecting data and for data interoperability. Even if the companies do not…
We could accelerate knowledge, save more children, and position drugs for more indications if we were able to conduct research [in Latin America]
Companies are becoming increasingly mature and want to extend value for dollars spent. The progress that has been made on digital in life sciences and healthcare…
The opportunities [in Saudi Arabia] are heightened by the leadership in the country and its Vision 2030; it encourages investment and favours private partnerships
We are not only working to localize manufacturing but also actively driving knowledge transfer for local professionals; the goal is to help them comply with the…
Prior to joining Amgros, I worked in pharma for nearly 15 years. Therefore, I will never be afraid of the industry; in fact, I have a…
Saudi Arabia is one of the most important and strategic markets in the region. The Kingdom is clearly committed to bettering the health of its citizens…
Despite being a relatively small country, our research output is extremely strong. However, where we have not traditionally been so strong is transforming that knowledge and…
COVID-19 has reaffirmed the importance of public-private partnerships within Danish healthcare, and we are seeing an increasing willingness from universities, hospitals, the Danish regions, and governmental…
